ALK and non-small cell lung carcinoma: More effective new-generation ALK tyrosine kinase inhibitors have been created to combat crizotinib resistance, and have shown efficacy in the treatment of both newly diagnosed patients and those with ALK-positive NSCLC who have become refractory to crizotinib (11, 12, 14, 15).